M. genitalium infection contributes to 10-35% of non-chlamydial non-gonococcal urethritis in men. In women, M. genitalium is associated with cervicitis and pelvic inflammatory disease (PID). Transmission of M. genitalium occurs through direct mucosal contact.
Introduction
Mycoplasmas are the smallest free-living micro-organisms. 1 In the urogenital tract, the relevant species are M. genitalium, Ureaplasma urealyticum, U. parvum, and M.
hominis. M. hominis and the ureaplasmas will not be dealt with in the present guideline.
Mycoplasma genitalium was first isolated in 1980. 2 
M. genitalium infection is
unequivocally associated with male NGU 3 and even stronger associated with nonchlamydial non-gonococcal urethritis (NCNGU). The prevalence of M. genitalium in men with NCNGU ranges from 10% to 35% 3 , thus contributing significantly to the overall burden of disease. In comparison, M. genitalium is detected in only 1% to 3.3%
of men and women in the general population. [4] [5] [6] In women, several studies have demonstrated the association between M. genitalium and urethritis, cervicitis, endometritis, and pelvic inflammatory disease (PID). [7] [8] [9] [10] [11] In a recent meta-analysis, 12 significant associations were found between M. genitalium and cervicitis (pooled odds ratio (OR) 1.66), and pelvic inflammatory disease (pooled OR 2.14). M. genitalium has been associated with preterm birth (pooled OR 1.89), and spontaneous abortion (pooled OR 1.82), but the prevalence of M. genitalium in pregnant women in Europe is low, 13, 14 and therefore, the relative importance of M. genitalium is probably small.
Studies have also shown an association with increased risk of tubal factor infertility (pooled OR 2.43). In sub-analyses that accounted for co-infections, Lis et al found these associations to be stronger. 12 Persistence of M. genitalium after treatment is associated with recurrent or persistent NGU, and up to 40% with this condition are M. genitalium positive. 15 In a recent metaanalysis, persistent M. genitalium was associated with a pooled odds ratio of 26 for persistent urethritis. 17 Thus, failure to eradicate M. genitalium leads to persistent or recurrent disease in the vast majority of men with persistent infection and diagnosis and optimal treatment is extremely important. The role of M. genitalium in facilitating HIV transmission, in particular in Sub-Saharan Africa 18-20 is another reason for concern when eradication fails due to inappropriate treatment.
Transmission
Transmission is primarily by direct genital-genital mucosal contact. Genital-anorectal transmission has been shown 21 and may play a role as M. genitalium is commonly found in the anal mucosa 22, 23 and the organism can be cultured from this site (Jensen, unpublished) . Oral-genital contact is less likely to contribute to any significant extent, as carriage of M. genitalium in the oro-pharynx is low. Mother-to-child transmission at birth has not been systematically studied, but M. genitalium has been detected in the respiratory tract of newborn children. 24 The risk of contracting M. genitalium per sexual encounter has not been determined, but because M. genitalium is present in lower concentration in genital tract specimens than C. trachomatis, 25 it could be considered slightly less contagious than chlamydia.
There are no estimates of the global burden of disease. In STI patients, the prevalence is usually from 60 to 85% of that of C. trachomatis, but in the general population, the ratio is generally significantly lower. 4, 6 Compared to C. trachomatis, the prevalence of M. genitalium infected patients appear
to peak approximately 5 years later for both men and women and to remain higher in the older age-groups.
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Clinical features
Urogenital infections

Symptoms and signs in women:
• Among STD clinic attendees, 40 -75% are asymptomatic.
10,11
• Symptoms are related to cervical and urethral infection and include increased or altered vaginal discharge (<50%), dysuria or urgency (30%) and, rarely, intermenstrual or post coital bleeding or menorrhagia. 10, 11, 28 • Cervicitis.
• Rectal and pharyngeal infections are usually asymptomatic.
• Lower abdominal pain (<20%) should raise suspicion of pelvic inflammatory disease (PID).
Complications in women:
12
• PID (endometritis, salpingitis)
• Tubal factor infertility (probably)
• Sexually acquired reactive arthritis (SARA).
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Symptoms and signs in men
• 70% symptomatic. 30 • Urethritis (acute, persistent, and recurrent)
• Dysuria
• Urethral discharge
• Balanoposthitis has been associated with M. genitalium infection in one study.
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Complications in men:
• SARA.
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• Epididymitis
Ocular infections
Ocular infections can result in conjunctivitis in adults 32 but is not systematically studied. Neonatal conjunctivitis has not been systematically studied
Indications for laboratory testing [IV; C]
Symptoms
• Symptoms or signs of urethritis in men
• Mucopurulent cervicitis
• Cervical or vaginal discharge with risk factor for STI
• Intermenstrual or post-coital bleeding
• Acute pelvic pain and/or PID
• Acute epididymo-orchitis in a male aged <50 years
Risk factors
• Any of the above symptoms in a regular sexual partner
• Persons with high-risk sexual behaviour (age <40 years and >3 new sexual contacts in the last year, more than 5 life-time partners and never tested)
• Sexual contact of persons with an STI or PID in particular contacts of M.
genitalium infected persons
• Before termination of pregnancy or other procedures, that breaks the cervical barrier.
• Regular testing of MSM, including anal sampling could be considered due to the risk of increased HIV transmission
Laboratory diagnostics [III; B]
Recommended diagnostic assays: With the widespread macrolide resistance in Europe, it is strongly recommended that all positive tests be followed up with an assay capable of detecting macrolide resistance mediating mutations. A variety of methods are available for this purpose, 27, [33] [34] [35] [36] [37] and the main determinant for the selection of an assay is the practical aspects from a laboratory point of view, and the sensitivity measured as the proportion of screening positive tests capable of being resistance typed. The latter aspect varies significantly between assays.
Determination of moxifloxacin resistance can also be carried out using molecular methods although the correlate between mutations in parC and in vitro moxifloxacin resistance is less clear. At present, detection of moxifloxacin resistance mediating mutations is probably not indicated on a routine basis in Europe, as the level of resistance is low (<5%) 38 but it may be considered in the Asia-Pacific region where moxifloxacin resistance is more common [39] [40] [41] or in patients having acquired the infection in this region.
Specimens
Due to the various assay formats, it is difficult to make firm conclusions regarding the optimal sample type. First void urine (FVU) from men and women provide a good diagnostic specimen which may be self-obtained. 26 No data regarding the importance of holding urine for a certain time are available, so procedures already in place for C. trachomatis sampling can be followed. Vaginal swab (physician or self-collected) also provide an appropriate sensitivity. [42] [43] [44] No data is available regarding time after exposure to testing, but in analogy to C.
trachomatis, a two-week period is considered the minimal incubation time. Anal samples are useful in MSM where as many as 70% of the infections will be missed if this site is not sampled, 45 but may also be relevant in women at risk. 23 The association between an anal infection and symptoms is uncertain, but the infection is likely to be transmitted if not detected and treated.
In most settings it will be appropriate to use the same sampling procedure as for C. • Patients with anal infection including MSM should be informed about the risk of transmission from this site and that the infection may be more difficult to eradicate. Consequently, a test of cure is important.
• Patients with M. genitalium infection should be screened for other STIs, 
Indications for therapy [IV; C]
• Identification of M. genitalium specific nucleic acid in a clinical specimen.
• On epidemiological grounds if a recent sexual contact has confirmed M.
genitalium infection (ideally specimens for M. genitalium NAAT should be collected before treatment and treatment should await the result of testing).
Therapy
Treatment of individuals with M. genitalium urogenital infection prevents sexual transmission and probably complications, including PID 5 and tubal-factor infertility. 12 Only few antimicrobial classes have activity against mycoplasmas including tetracyclines, macrolides, and fluoroquinolones.
Doxycycline has a poor efficacy [46] [47] [48] [49] with microbiological cure rates between 30% and 40%, whereas azithromycin given as a 1 g single dose has a cure rate of approximately 85% in macrolide susceptible infections. 46, 47 A rapidly increasing prevalence of macrolide resistance, most likely due to widespread use of azithromycin as a 1 g single dose without test of cure, however, is drastically decreasing the overall cure rate.
Azithromycin given as an extended regimen with 500 mg day one followed by 250 mg days 2-5 (1.5g total dose) is recommended as the primary choice for treatment of M.
genitalium infections. Using extended azithromycin or other macrolide antibiotics after failure with the 1g single dose regimen will not eradicate M. genitalium.
Macrolide resistance rates varies significantly geographically, but where azithromycin 1g single dose is used for treatment of NGU, it is usually found in 30-45% of samples. 27, 38, 41, 50 Josamycin is widely used in Russia with 500 mg three times a day for 10 days, but will not eradicate macrolide resistant strains.
Moxifloxacin is the most commonly used second line antimicrobial. It is bactericidal and has a cure rate approaching 100% in infections with susceptible strains. 16, [51] [52] [53] However, resistance has developed with treatment failures in up to 30%, primarily in patients from the Asia-Pacific region. A significant proportion of the M. genitalium strains had concurrent macrolide resistance mediating mutations leaving very few available treatment options. 40, [54] [55] [56] Pristinamycin is the only antimicrobial with documented activity in patients failing both azithromycin, moxifloxacin, and in many cases also extended dosage doxycycline (100 mg twice daily for 14 days). 56 In Europe, it is registered only in France, but can be acquired after special permit in most European countries. It should only be used in the maximal recommended dose of 1g four times a day for 10 days (oral) as these patients are facing their last known active antimicrobial therapy and dose reduction may lead to failure.
Recommended treatment for uncomplicated M. genitalium infection in the absence of macrolide resistance mediating mutations [IIb;B]
• Azithromycin 500 mg on day one, then 250 mg od days 2-5 (oral)
• Josamycin 500 mg 3 times daily for 10 days [IV.C]
Recommended treatment for uncomplicated macrolide resistant M. genitalium infection [IIb;B]
• Moxifloxacin 400 mg od for 7 -10 days (oral). The optimal duration of treatment is uncertain and a few observational studies have found higher curerate after longer treatment in cervicitis. • Doxycycline 100 mg two times daily for 14 days can be tried and will eradicate M. genitalium from approximately 30% of the patients, but the patient must be informed about the poor eradication rate and accept to comply with advice regarding sexual abstinence or condom use.
• Pristinamycin 1g four times daily for 10 days (oral). The patient should be informed about the need to comply strictly with the dosage scheme.
Recommended treatment for complicated M. genitalium infection (PID, epididymitis) [IV;C]
• Moxifloxacin 400 mg od for 14 days (oral).
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Partner notification
• Contact notification should be performed and documented by appropriately trained professionals at the time of diagnosis to improve outcome [IV;C]
• Sexual contacts should be contacted and offered testing together with counselling and treatment for M. genitalium infection (same antimicrobial as index patient) and testing for other STIs [IV; C]
• All sexual contacts within the preceding 6 months of onset of symptoms or diagnosis should ideally be evaluated, tested and treated [IV; C].
• If sexual contacts do not attend for evaluation and testing, epidemiological treatment should be offered to a current partner with the same regimen as given to the index patient [IV; C]
Follow-up and test of cure (TOC)
• A TOC should be routinely performed in all patients due to the high prevalence In patients responding to treatment, M. genitalium will be undetectable within one week in most patients, but tests may become temporarily false negative in patients failing treatment.
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Qualifying statement:
Decisions to follow these recommendations must be based on professional clinical judgement, consideration of individual patient circumstances and available resources.
All possible care has been undertaken to ensure publication of the correct dosage of medication and route of administration. However, it remains the responsibility of the prescribing clinician to ensure the accuracy and appropriateness of the medication they prescribe.
